...
首页> 外文期刊>Protein Expression and Purification >One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry
【24h】

One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry

机译:使用组合化学开发的合成肽一步一步亲和纯化重组尿激酶型纤溶酶原激活剂受体

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Several lines of evidence have pointed to a role of urokinase-type plasminogen activator receptor (uPAR) as a modulator of certain biochemical processes that are active during tumor invasion and metastasis. Consequently, the structure and function of this receptor have been studied extensively, using recombinantly produced uPAR that has been purified by either affinity chromatography using its cognate ligand, the urokinase-type plasminogen activator (uPA), or a monoclonal anti-uPAR antibody (R2), or by hydroxyapatite. Here, we present a new method for the efficient one-step affinity purification of recombinant uPAR exploiting a high-affinity synthetic peptide antagonist (AE152). The corresponding parent peptide was originally identified in a random phage-displa library and subsequently subjected to affinity maturation by combinatorial chemistry. This study compares the affinity purification of a soluble, recombinant uPAR using the monoclonal antibody R2 or the peptide AE152 immobilized on Sepharose. The two affinity ligands perform equally well in purifying uPAR from Drosophila melanogaster Schneider 2 cell culture medium and yield products of comparable purity, activity, and stability as judged by SDS-PAGE, size exclusion chromatography and surface plasmon resonance analysis. The general availability of peptide synthesis renders the present AE152-based affinity purification of uPAR more accessible than the traditional protein-based affinity purification strategies. In this way, large amounts of recombinant uPAR can conveniently be purified for further structural and functional studies. (c) 2006 Elsevier Inc. All rights reserved.
机译:有几条证据表明,尿激酶型纤溶酶原激活剂受体(uPAR)作为某些生化过程的调节剂,在肿瘤侵袭和转移过程中很活跃。因此,已使用重组产生的uPAR对该受体的结构和功能进行了广泛研究,该uPAR已通过使用其同源配体的亲和色谱,尿激酶型纤溶酶原激活剂(uPA)或单克隆抗uPAR抗体(R2)进行了纯化。 )或羟基磷灰石。在这里,我们提出了一种利用高亲和力合成肽拮抗剂(AE152)有效地一步纯化重组uPAR的新方法。相应的亲本肽最初是在随机噬菌体-displa文库中鉴定的,随后通过组合化学进行亲和力成熟。这项研究比较了使用单克隆抗体R2或固定在琼脂糖凝胶上的肽AE152亲和纯化可溶性重组uPAR的方法。两种亲和配体在从果蝇Schneider 2细胞培养基中纯化uPAR方面表现同样出色,并且产生的纯度,活性和稳定性相当的产品,如SDS-PAGE,尺寸排阻色谱法和表面等离振子共振分析所判断。与传统的基于蛋白质的亲和力纯化策略相比,肽合成的普遍可用性使得本发明基于uAE的基于AE152的亲和力纯化更容易获得。这样,可以方便地纯化大量的重组uPAR,以用于进一步的结构和功能研究。 (c)2006 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号